Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X:
“The SERENA-6 PFS2 results were presented at ASCO26 . The full-text is now published, but the OS data remain immature. The current curves do not show a clear separation. Whether an OS benefit will emerge with longer F/U remains an open question.”
Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared the post by Yakup Ergün, adding:
“Don’t miss the thoughtful accompanying editorial by Carmine Valenza.”
Title: Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Authors: Nicholas C Turner, Erica L Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Adam M Brufsky, Peter A Fasching, Zbigniew Nowecki, Javier Pascual, Nuri Karadurmus, Einav Gal-Yam, Wei-Pang Chung, Seock-Ah Im, Alberto Zambelli, Florence Dalenc, Mafalda Oliveira, Hiroshi Ishiguro, Chiun-Sheng Huang, Teresa Klinowska, Steven Fox, Christopher Morrow, Lídia Robert, Cynthia Huang-Bartlett, François-Clément Bidard
2. Title: Now or later? Switching therapies in metastatic breast cancer
Authors: Carmine Valenza, Meredith M Regana, Harold J Bursteina
Other articles featuring Yakup Ergün on OncoDaily.